EGFR Positive Lung Cancer Latest Advances

Correction to "Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer".

Journal: Molecular oncology

Published: March 27, 2026

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: March 18, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy.

Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology

Published: February 24, 2026

Triple-Dose Furmonertinib for Leptomeningeal Metastases in Advanced Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

Journal: Cureus

Published: February 23, 2026

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.

Journal: ACS medicinal chemistry letters

Published: February 13, 2026

A CRISPR/Cas9-regulated dual-ring topological allosteric probe for detection of the EGFR L858R resistance mutation in CTCs.

Journal: Analytical methods : advancing methods and applications

Published: February 13, 2026

Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.

Journal: JAMA oncology

Published: February 12, 2026

In-Silico Predictions of Drug Resistance in Lung Cancers With EGFR Mutation.

Journal: Proceedings of the Platform for Advanced Scientific Computing Conference

Published: February 11, 2026

When EGFR meets MET: Dual blockade as the next post-TKI standard?

Journal: Med (New York, N.Y.)

Published: February 10, 2026

Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.

Journal: Bioorganic & medicinal chemistry

Published: February 07, 2026

The synthesis and biological evaluation of novel deuterated and non-deuterated aminobenzenesulfonamide derivatives as EGFR inhibitor.

Journal: Bioorganic & medicinal chemistry

Published: February 04, 2026

EGFR Positive Lung Cancer Latest Advances

Find the Latest Research About EGFR Positive Lung Cancer

Correction to "Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer".

Correction to "Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer".

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy.

Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy.

Triple-Dose Furmonertinib for Leptomeningeal Metastases in Advanced Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

Triple-Dose Furmonertinib for Leptomeningeal Metastases in Advanced Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting.

A CRISPR/Cas9-regulated dual-ring topological allosteric probe for detection of the EGFR L858R resistance mutation in CTCs.

A CRISPR/Cas9-regulated dual-ring topological allosteric probe for detection of the EGFR L858R resistance mutation in CTCs.

Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.

Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.

In-Silico Predictions of Drug Resistance in Lung Cancers With EGFR Mutation.

In-Silico Predictions of Drug Resistance in Lung Cancers With EGFR Mutation.

When EGFR meets MET: Dual blockade as the next post-TKI standard?

When EGFR meets MET: Dual blockade as the next post-TKI standard?

Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.

Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation.

The synthesis and biological evaluation of novel deuterated and non-deuterated aminobenzenesulfonamide derivatives as EGFR inhibitor.

The synthesis and biological evaluation of novel deuterated and non-deuterated aminobenzenesulfonamide derivatives as EGFR inhibitor.